These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32543911)

  • 1. The WATCHMAN left atrial appendage closure device for patients with atrial fibrillation: current status and future perspectives.
    Wintgens LIS; Maarse M; Swaans MJ; Rensing BJWM; Van Dijk VF; Boersma LVA
    Expert Rev Med Devices; 2020 Jul; 17(7):615-626. PubMed ID: 32543911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data.
    Reddy VY; Akehurst RL; Gavaghan MB; Amorosi SL; Holmes DR
    J Am Heart Assoc; 2019 Jul; 8(13):e011577. PubMed ID: 31230500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
    Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter ablation in combination with left atrial appendage closure for atrial fibrillation.
    Swaans MJ; Alipour A; Rensing BJ; Post MC; Boersma LV
    J Vis Exp; 2013 Feb; (72):e3818. PubMed ID: 23486416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of percutaneous Watchman 2.5 device versus Amplatzer Amulet for left atrial appendage closure in patients with non-valvular atrial fibrillation: A systematic review and study-level meta-analysis.
    Yasmin F; Ali E; Moeed A; Zaidi F; Umar M; Virwani V
    PLoS One; 2024; 19(2):e0295804. PubMed ID: 38354181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct current cardioversion practices following percutaneous left atrial appendage closure.
    Bhuta S; Shaaban A; Binda NC; Antaki J; Augostini RS; Kalbfleisch SJ; Savona SJ; Okabe T; Houmsse M; Afzal MR; Daoud EG; Hummel JD
    J Cardiovasc Electrophysiol; 2023 Aug; 34(8):1698-1705. PubMed ID: 37493499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
    Reddy VY; Möbius-Winkler S; Miller MA; Neuzil P; Schuler G; Wiebe J; Sick P; Sievert H
    J Am Coll Cardiol; 2013 Jun; 61(25):2551-6. PubMed ID: 23583249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term outcome after left atrial appendage occlusion with the AMPLATZER Amulet and WATCHMAN device: results from the ORIGINAL registry (saxOnian RegIstry analyzinG and followINg left atrial Appendage cLosure).
    Kretzler L; Mues C; Wunderlich C; Langbein A; Spitzer SG; Gerk U; Schellong S; Ketteler T; Neuser H; Schwefer M; Strasser R; Ibrahim K; Schoen S; Christoph M
    BMC Cardiovasc Disord; 2022 Jun; 22(1):271. PubMed ID: 35710343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation.
    Onalan O; Crystal E
    Stroke; 2007 Feb; 38(2 Suppl):624-30. PubMed ID: 17261703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
    Ramlawi B; Abu Saleh WK; Edgerton J
    Methodist Debakey Cardiovasc J; 2015; 11(2):100-3. PubMed ID: 26306127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation.
    Black-Maier E; Piccini JP; Granger CB
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latest outcomes of transcatheter left atrial appendage closure devices and direct oral anticoagulant therapy in patients with atrial fibrillation over the past 5 years: a systematic review and meta-analysis.
    Takeda K; Tsuboko Y; Iwasaki K
    Cardiovasc Interv Ther; 2022 Oct; 37(4):725-738. PubMed ID: 35098478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort.
    Schrag M; Mac Grory B; Nackenoff A; Eaton J; Mistry E; Kirshner H; Yaghi S; Ellis CR
    Transl Stroke Res; 2021 Apr; 12(2):259-265. PubMed ID: 32770310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial appendage orifice diameter measured with trans-esophageal echocardiography is independently related with peri-device leakage after Watchman device implantation.
    Chen YY; Zhang YH; Chen X; Huang WP; Xu B; Su X; Chen YH
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1831-1839. PubMed ID: 31321654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
    Kar S; Doshi SK; Alkhouli M; Camm AJ; Coylewright M; Gibson MC; Granger CB; Gurol ME; Huber K; Mansour M; Nair DG; Natale A; Pocock SJ; Reddy VR; Saliba W; Christen T; Allocco DJ; Ellenbogen KA; Leon MB
    Am Heart J; 2023 Oct; 264():123-132. PubMed ID: 37279840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Beard SM; Holmes DR
    J Am Coll Cardiol; 2015 Dec; 66(24):2728-2739. PubMed ID: 26616031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current State of Left Atrial Appendage Closure.
    Kosturakis R; Price MJ
    Curr Cardiol Rep; 2018 Apr; 20(6):42. PubMed ID: 29680999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.